Activity of faropenem for ciprofloxacin-resistant bacteria

Laura Piddock; Margaret Johnson; Mark Webber

doi:10.1093/jac/dkg373

Activity of faropenem for ciprofloxacin-resistant bacteria

Laura Piddock, Margaret Johnson, Mark Webber

Immunology and Immunotherapy

Research output: Contribution to journal › Article

7 Citations (Scopus)

Abstract

AIM: To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates. METHODS: The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium. RESULTS: Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species. CONCLUSIONS: Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.

Original language	English
Pages (from-to)	500-2
Number of pages	3
Journal	Journal of Antimicrobial Chemotherapy
Volume	52
Issue number	3
Early online date	13 Aug 2003
DOIs	https://doi.org/10.1093/jac/dkg373
Publication status	Published - 13 Aug 2003

Keywords

fluoroquinolone
MIC
carbapenem

Access to Document

10.1093/jac/dkg373

Cite this

@article{196fd1b142df4f9b9fe084623afb0edb,

title = "Activity of faropenem for ciprofloxacin-resistant bacteria",

abstract = "AIM: To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates. METHODS: The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium. RESULTS: Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species. CONCLUSIONS: Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.",

keywords = "fluoroquinolone, MIC, carbapenem",

author = "Laura Piddock and Margaret Johnson and Mark Webber",

year = "2003",

month = aug,

day = "13",

doi = "10.1093/jac/dkg373",

language = "English",

volume = "52",

pages = "500--2",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "1460-2091",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Activity of faropenem for ciprofloxacin-resistant bacteria

AU - Piddock, Laura

AU - Johnson, Margaret

AU - Webber, Mark

PY - 2003/8/13

Y1 - 2003/8/13

N2 - AIM: To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates. METHODS: The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium. RESULTS: Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species. CONCLUSIONS: Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.

AB - AIM: To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates. METHODS: The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium. RESULTS: Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species. CONCLUSIONS: Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.

KW - fluoroquinolone

KW - MIC

KW - carbapenem

UR - http://www.scopus.com/inward/record.url?scp=0141852767&partnerID=8YFLogxK

U2 - 10.1093/jac/dkg373

DO - 10.1093/jac/dkg373

M3 - Article

C2 - 12917244

SN - 1460-2091

VL - 52

SP - 500

EP - 502

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 3

ER -

Activity of faropenem for ciprofloxacin-resistant bacteria

Abstract

Keywords

Access to Document

Fingerprint

Cite this